Transparency data

Non-tech. summaries 2015: projects on oncology

Projects granted during 2015 that have a primary purpose of basic research: oncology.

From:
Home Office
Published
21 June 2016

Documents

Non-technical summaries: projects granted in 2015, volume 17

PDF, 1010 KB, 140 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This document outlines the projects granted under the Animals (Scientific Procedures) Act 1986 during 2015 with a primary purpose of basic research: oncology.

It contains a full list of the 41 projects that were granted.

The projects covered are:

  • analysing the genetic and epigenetic control of cancer (cancer, genetics, epigenetics)

  • helicobacter pylori virulence, immunity and disease (helicobacter pylori, virulence factors, carcinogenesis)

  • models of intestinal and genetically related tumours (colorectal tumours, cancer evolution, genetics)

  • radiation-induced leukaemogenesis (leukaemia, radio-sensitive, bone marrow)

  • investigation of tumourigenic pathways (tumour, oncogene, signalling)

  • new strategies for the diagnosis and treatment of glioma (brain tumour, glioma, diagnosis, treatment)

  • glioblastoma treatment and resistance (cancer, brain, rodent, treatment, resistance)

  • in vivo models of childhood leukaemia (childhood leukaemia, new therapies)

  • in vivo studies of tumour associated fibroblasts (fibroblast, cancer, mouse, genetically modified)

  • experimental cancer chemotherapy (xenograft chemotherapy non-genotoxic)

  • arginine methylation and tumourigenesis (cancer, genetically engineered mice)

  • epigenetics of cell senescence, cancer and ageing (epigenetics, cancer, ageing, mouse models)

  • analysis of stressors, nutrition and ageing in cancer (stress, cancer, treatment, ageing, diagnostics)

  • tumour progression in zebrafish models of cancer (cancer, cell signalling, biosensor, tumour microenvironment, optical projection tomography (OPT))

  • investigating human pancreatic cancer in mice (pancreatic cancer, genes, therapy)

  • analysing cancer metastasis and therapy failure (cancer, cell movement, imaging, metastasis, treatment)

  • elucidating novel actionable mutations in cancer (enzymes, genetics, cancer drivers, drug pathways, tumour-suppressing enzymes)

  • aspects of cancer regulation (cancer, macrophage, dormancy, lncRNAs)

  • cellular and molecular haematopoietic dynamics in health and disease (stem cells, haematopoiesis, transplantation, intravital microscopy, stem cell niche)

  • imaging of cell therapy in tumour models (tumour, cell therapy, imaging)

  • pancreatic cancer – improving our understanding and therapeutic options (pancreatic cancer, therapeutic, genotype/phenotype)

  • targeting the mechanisms of tumour vascularisation (cancer, metastasis, tumour stroma, angiogenesis, therapy)

  • defining mechanisms of cancer progression and dissemination (cancer, metastasis, microenvironment, imaging)

  • assessment of tumour initiation and metastatic spread (cancer, metastasis, drugs, endocrine resistance)

  • RUNX1 functions in normal tissues and cancers (haematopoiesis, leukaemia, cancer, reprogramming)

  • cytokine signalling in development and disease (TGF-13 superfamily signalling, transcription, cancer, embryonic development, signal transduction)

  • NKT cells and related immunity in health and disease (cancer obesity NKT (cells) immunotherapy)

  • signalling pathways in cancer (cancer, protein kinase, protein phosphatise)

  • mouse models of prostate cancer initiation and progression (cancer, prostate, tumour-initiating cells, metastasis, therapy)

  • characterisation of cellular heterogeneity in ovarian cancer (stem cells, xenotransplantation, cancer, lineage- tracing)

  • mouse models of KRAS-driven cancer progression & therapy (lung cancer, oncogene, metastasis, therapy)

  • inflammation and viral tumourigenesis (EBV, cancer, chronic inflammation, anti-oxidant)

  • mouse models of human cancer (cancer, GEMS, therapy, transplantation)

  • investigating epithelial cancer in vivo (colorectal cancer, pancreatic cancer, therapy)

  • cancer imaging and drug development (cancer, imaging, diagnosis, early response, drug development)

  • p53-family in physiology and cancer (cancer, aging, development, metabolism)

  • novel functions of p53 mutations in tumour progression (tumours, mutant p53, RCP, engulfment)

  • combining immunotherapy with current cancer treatments (cancer, oncolytic virus, magnetic particles, MRI, macrophages)

  • validation of tumour vascular targets and associated therapies (angiogenesis, cancer, vascular targets)

  • models advancing knowledge and treatment of paediatric brain cancer (paediatric, brain, cancer, treatment, biology)

  • evaluation of novel drug formulations in pancreatic cancer (cancer, drugs, nanotechnology, imaging, targeting)

Published 21 June 2016

Related content